JP2006510382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006510382A5 JP2006510382A5 JP2004562300A JP2004562300A JP2006510382A5 JP 2006510382 A5 JP2006510382 A5 JP 2006510382A5 JP 2004562300 A JP2004562300 A JP 2004562300A JP 2004562300 A JP2004562300 A JP 2004562300A JP 2006510382 A5 JP2006510382 A5 JP 2006510382A5
- Authority
- JP
- Japan
- Prior art keywords
- data set
- profile data
- sample
- subject
- panel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000015181 infectious disease Diseases 0.000 claims description 143
- 238000000034 method Methods 0.000 claims description 112
- 210000004369 blood Anatomy 0.000 claims description 83
- 239000008280 blood Substances 0.000 claims description 83
- 238000005259 measurement Methods 0.000 claims description 80
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 70
- 238000011282 treatment Methods 0.000 claims description 69
- 239000003814 drug Substances 0.000 claims description 49
- 208000031729 Bacteremia Diseases 0.000 claims description 48
- 229940079593 drug Drugs 0.000 claims description 43
- 230000003321 amplification Effects 0.000 claims description 41
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 41
- 230000001225 therapeutic effect Effects 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 30
- 244000052769 pathogen Species 0.000 claims description 28
- 238000003556 assay Methods 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 210000001124 body fluid Anatomy 0.000 claims description 22
- 239000010839 body fluid Substances 0.000 claims description 22
- 230000009885 systemic effect Effects 0.000 claims description 22
- 208000024891 symptom Diseases 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 19
- 235000016709 nutrition Nutrition 0.000 claims description 15
- 230000037081 physical activity Effects 0.000 claims description 15
- 230000001717 pathogenic effect Effects 0.000 claims description 13
- 238000003860 storage Methods 0.000 claims description 11
- 244000005700 microbiome Species 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 238000003384 imaging method Methods 0.000 claims description 6
- 238000013507 mapping Methods 0.000 claims description 6
- 230000002503 metabolic effect Effects 0.000 claims description 6
- 238000002562 urinalysis Methods 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 235000004252 protein component Nutrition 0.000 claims description 5
- 238000011002 quantification Methods 0.000 claims description 5
- 238000011156 evaluation Methods 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 2
- 238000007620 mathematical function Methods 0.000 claims description 2
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims 8
- 102000016605 B-Cell Activating Factor Human genes 0.000 claims 8
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims 8
- 102100039928 Gamma-interferon-inducible protein 16 Human genes 0.000 claims 8
- 102100040352 Heat shock 70 kDa protein 1A Human genes 0.000 claims 8
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims 8
- 101000960209 Homo sapiens Gamma-interferon-inducible protein 16 Proteins 0.000 claims 8
- 101001037759 Homo sapiens Heat shock 70 kDa protein 1A Proteins 0.000 claims 8
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims 8
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 claims 8
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 8
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 8
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 claims 8
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 description 258
- 239000000523 sample Substances 0.000 description 142
- 230000004968 inflammatory condition Effects 0.000 description 71
- 210000004027 cell Anatomy 0.000 description 57
- 230000002757 inflammatory effect Effects 0.000 description 56
- 206010061218 Inflammation Diseases 0.000 description 54
- 230000004054 inflammatory process Effects 0.000 description 54
- 108090000623 proteins and genes Proteins 0.000 description 50
- 230000006870 function Effects 0.000 description 42
- 210000001519 tissue Anatomy 0.000 description 39
- 208000035473 Communicable disease Diseases 0.000 description 37
- 241000588724 Escherichia coli Species 0.000 description 36
- 206010039073 rheumatoid arthritis Diseases 0.000 description 36
- 230000004044 response Effects 0.000 description 27
- 230000000875 corresponding effect Effects 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 22
- 238000012544 monitoring process Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 238000000338 in vitro Methods 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 16
- 241000219094 Vitaceae Species 0.000 description 15
- 230000008859 change Effects 0.000 description 15
- 235000021021 grapes Nutrition 0.000 description 15
- 238000004422 calculation algorithm Methods 0.000 description 14
- 230000036961 partial effect Effects 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 13
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 12
- 208000038016 acute inflammation Diseases 0.000 description 12
- 230000006022 acute inflammation Effects 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 208000014674 injury Diseases 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 230000008733 trauma Effects 0.000 description 12
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 229960000485 methotrexate Drugs 0.000 description 10
- 230000003287 optical effect Effects 0.000 description 10
- 229960004618 prednisone Drugs 0.000 description 10
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 10
- 206010035664 Pneumonia Diseases 0.000 description 9
- 238000004820 blood count Methods 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- 230000036760 body temperature Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 206010014665 endocarditis Diseases 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 9
- 230000000149 penetrating effect Effects 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 208000019206 urinary tract infection Diseases 0.000 description 9
- 208000035143 Bacterial infection Diseases 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 208000022362 bacterial infectious disease Diseases 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 7
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 description 7
- 208000036142 Viral infection Diseases 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 206010017533 Fungal infection Diseases 0.000 description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 6
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 6
- 208000031888 Mycoses Diseases 0.000 description 6
- 208000030852 Parasitic disease Diseases 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 229960001680 ibuprofen Drugs 0.000 description 6
- 239000012678 infectious agent Substances 0.000 description 6
- 239000002085 irritant Substances 0.000 description 6
- 231100000021 irritant Toxicity 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 229940116176 remicade Drugs 0.000 description 6
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 6
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 5
- 102100039065 Interleukin-1 beta Human genes 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 238000002123 RNA extraction Methods 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 230000036281 parasite infection Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000004544 DNA amplification Effects 0.000 description 4
- 206010058874 Viraemia Diseases 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 208000003435 Optic Neuritis Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 230000009274 differential gene expression Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000021 stimulant Substances 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 206010049590 Upper respiratory tract inflammation Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 230000007940 bacterial gene expression Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229940073621 enbrel Drugs 0.000 description 2
- 230000001632 homeopathic effect Effects 0.000 description 2
- 229940082177 ibuprofen 800 mg Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- -1 physical Substances 0.000 description 2
- 230000008288 physiological mechanism Effects 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- 229960005266 polymyxin b Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 244000052613 viral pathogen Species 0.000 description 2
- 101150016096 17 gene Proteins 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 101150094083 24 gene Proteins 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 1
- 101001097889 Homo sapiens Platelet-activating factor acetylhydrolase Proteins 0.000 description 1
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 102100037518 Platelet-activating factor acetylhydrolase Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
- 101100187345 Xenopus laevis noto gene Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 210000005256 gram-negative cell Anatomy 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43525702P | 2002-12-19 | 2002-12-19 | |
| PCT/US2003/040551 WO2004057034A1 (en) | 2002-12-19 | 2003-12-19 | Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010111560A Division JP2010227111A (ja) | 2002-12-19 | 2010-05-13 | 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006510382A JP2006510382A (ja) | 2006-03-30 |
| JP2006510382A5 true JP2006510382A5 (enExample) | 2010-07-01 |
Family
ID=32682206
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004562300A Pending JP2006510382A (ja) | 2002-12-19 | 2003-12-19 | 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け |
| JP2010111560A Pending JP2010227111A (ja) | 2002-12-19 | 2010-05-13 | 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010111560A Pending JP2010227111A (ja) | 2002-12-19 | 2010-05-13 | 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1579008A1 (enExample) |
| JP (2) | JP2006510382A (enExample) |
| CN (1) | CN1751129B (enExample) |
| AU (1) | AU2003303238B2 (enExample) |
| BR (1) | BR0317612A (enExample) |
| CA (1) | CA2511237A1 (enExample) |
| MX (1) | MXPA05006804A (enExample) |
| WO (1) | WO2004057034A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2505921A1 (en) | 2002-11-12 | 2004-05-27 | Becton, Dickinson And Company | Diagnosis of sepsis or sirs using biomarker profiles |
| EP2128270B1 (en) | 2003-08-08 | 2012-10-03 | Genenews Inc. | Osteoarthritis biomarkers and uses thereof |
| BRPI0609302A2 (pt) | 2005-04-15 | 2011-10-11 | Becton Dickinson Co | métodos para prever o desenvolvimento de sepse e para diagnosticar sepse em um indivìduo a ser testado, microarranjo, kit para prever o desenvolvimento de sepse em um indivìduo a ser testado, produto de programa de computador, computador, sistema de computador para determinar se um indivìduo é susceptìvel de desenvolver sepse, sinal digital embutido em uma onda portadora, e, interface gráfica de usuário para determinar se um indivìduo é susceptìvel de desenvolver sepse |
| AU2006294477A1 (en) * | 2005-09-27 | 2007-04-05 | Source Mdx | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis |
| CA2652239A1 (en) * | 2006-05-16 | 2007-11-29 | Source Mdx | Assessment of effect of an agent on a human biological condition using rodent gene expression panels |
| WO2008048986A2 (en) * | 2006-10-17 | 2008-04-24 | Children's Hospital Medical Center | Gene array technique for predicting response in inflammatory bowel diseases |
| DE102007036678B4 (de) * | 2007-08-03 | 2015-05-21 | Sirs-Lab Gmbh | Verwendung von Polynukleotiden zur Erfassung von Genaktivitäten für die Unterscheidung zwischen lokaler und systemischer Infektion |
| TWI600759B (zh) | 2010-04-02 | 2017-10-01 | 可娜公司 | 藉由抑制群落刺激因子３（ｃｓｆ３）之天然反義轉錄物以治療ｃｓｆ３相關疾病 |
| GB201304626D0 (en) * | 2013-03-14 | 2013-05-01 | Univ Cardiff | Method of identifying a bacterial infection |
| BR112017019373A2 (pt) * | 2015-03-12 | 2018-06-05 | Koninklijke Philips N.V. | método implementado por computador, e, mídia legível por computador |
| US11031119B2 (en) * | 2019-11-13 | 2021-06-08 | Cube Click, Inc. | Dental images processed with deep learning for national security |
| CN118824376B (zh) * | 2024-09-18 | 2025-01-21 | 江苏省疾病预防控制中心(江苏省预防医学科学院) | 基于元学习技术的呼吸系统传染病人工智能辅助筛查系统 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0960214A4 (en) * | 1996-12-06 | 2004-08-04 | Urocor Inc | Diagnosis of disease status on HAnd from mRNA profiles |
| DK1198585T3 (da) * | 1999-06-28 | 2007-10-15 | Source Precision Medicine Inc | Fremgangsmåde til karakterisering af en biologisk tilstand ved anvendelse af kalibrerede genudtrykkelsesprofiler |
| US6964850B2 (en) * | 2001-11-09 | 2005-11-15 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
-
2003
- 2003-12-19 AU AU2003303238A patent/AU2003303238B2/en not_active Ceased
- 2003-12-19 CN CN200380109850.5A patent/CN1751129B/zh not_active Expired - Lifetime
- 2003-12-19 MX MXPA05006804A patent/MXPA05006804A/es unknown
- 2003-12-19 EP EP03808491A patent/EP1579008A1/en not_active Withdrawn
- 2003-12-19 BR BR0317612-6A patent/BR0317612A/pt not_active IP Right Cessation
- 2003-12-19 WO PCT/US2003/040551 patent/WO2004057034A1/en not_active Ceased
- 2003-12-19 CA CA002511237A patent/CA2511237A1/en not_active Abandoned
- 2003-12-19 JP JP2004562300A patent/JP2006510382A/ja active Pending
-
2010
- 2010-05-13 JP JP2010111560A patent/JP2010227111A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508505A (ja) | 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定 | |
| JP2010227111A (ja) | 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け | |
| AU784233B2 (en) | Systems and methods for characterizing a biological condition or agent using calibrated gene expression profiles | |
| Ruau et al. | Sex differences in reported pain across 11,000 patients captured in electronic medical records | |
| US20080233573A1 (en) | Gene expression profiling for identification, monitoring and treatment of transplant rejection | |
| JP2005508505A5 (enExample) | ||
| EP1945814A2 (en) | Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis | |
| JP2020535823A (ja) | 標的遺伝子発現の数学的モデル化を使用する、ｊａｋ−ｓｔａｔ３細胞シグナル伝達経路活性の評価 | |
| JP2006510382A5 (enExample) | ||
| US20110306512A1 (en) | Gene Expression Profiling for Identification, Monitoring, and Treatment of Osteoarthritis | |
| AU2003303238A2 (en) | Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles | |
| CN105506074B (zh) | 一种用于精神分裂症诊断的lncRNA标志物及试剂盒 | |
| EP2069533A2 (en) | Gene expression profiling for identification, monitoring and treatment of multiple sclerosis | |
| Sinnott et al. | Differential gene expression in prostate tissue according to ejaculation frequency | |
| US20080227655A1 (en) | Assessment of effect of an agent on a human biological condition using rodent gene expression panels | |
| Welch et al. | Protocol for the REBOUND study: a cohort study to uncover fundamental mechanisms of accelerated ageing and impaired resilience following cancer surgery and treatment | |
| WO2006138561A2 (en) | Gene expression profiling for identification and monitoring of multiple sclerosis | |
| Öner Talmaç et al. | Determination of IL-17, BCL-3 and IκBζ expression levels in the gingival crevicular fluid of psoriasis patients | |
| Zainal Abidin et al. | Let‐7e as Potential Diagnostic Biomarkers in Early Detection of Peri‐Implant Diseases: A Cross‐Sectional Study | |
| HK1169190A (en) | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles | |
| US20150045244A1 (en) | Method for determining rheumatoid arthritis activity indicator, and biomarker used therein |